Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
AffiliationTargeted Therapy Group, Institute of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre, Manchester Academic Health Sciences Centre , Manchester
MetadataShow full item record
AbstractNearly two decades ago rituximab heralded a new era in management of B cell malignancies significantly increasing response rates and survival. However, despite clear therapeutic advantage, significant numbers of patients become refractory to anti-CD20 mAb therapy, suggesting urgent improvements are required. It is now well recognized that the suppressive tumor microenvironment plays an important role in the outcome of anti-CD20 mAb therapy and that manipulation of this environment may improve the efficacy and produce long-term tumor control. The past few years have seen a surge of interest in immunomodulatory agents capable of overwriting immune suppressive networks into favorable clinical outcome. Currently, a number of such combinations with anti-CD20 mAb is under evaluation and some have produced encouraging outcomes in rituximab refractory disease. In this review, we give an outline of anti-CD20 mAbs and explore the combinations with immunomodulatory agents that enhance antitumor immunity through targeting stimulatory or inhibitory pathways and have proven potential to synergize with anti-CD20 mAb therapy. These agents, primarily mAbs, target CTLA-4, PD-1/PD-L1, and CD40.
Citationoving therapeutic activity of anImprti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. 2016:1-12 Leuk Lymphoma
JournalLeukemia & Lymphoma
- GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
- Authors: Robak T
- Issue date: 2009 Jun
- New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
- Authors: Robak T, Robak E
- Issue date: 2011 Feb 1
- The emerging role of immune checkpoint inhibition in malignant lymphoma.
- Authors: Hude I, Sasse S, Engert A, Bröckelmann PJ
- Issue date: 2017 Jan
- Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
- Authors: Plosker GL, Figgitt DP
- Issue date: 2003
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
- Authors: Mahoney KM, Freeman GJ, McDermott DF
- Issue date: 2015 Apr 1